You are here

Biogen Makes Play for Big Stake in Samsung Bioepis

Puts down $700 million to buy nearly 50% of Samsung.

In a move analysts of the biosimilars market have been looking for, Biogen decided to jump into a pool with both feet that it merely stuck its toe in in 2011. Biogen slapped down $700 million in its bid to buy 49.9% of Samsung Bioepis, Endpoints News reports.

Apparently, the move springs from a change in CEOs. Back in 2011, it was George Scangos. Today it is Michel Vounatsos. “This option allows us to increase our ownership share in a leading biosimilar company at what we believe are attractive terms,” Vounatsos tells Endpoints News. “We look forward to building an important relationship with Samsung BioLogics.”

Source: Endpoints News

Recent Headlines

Possible First Treatment Option for Rare Autoimmune Disease of the CNS
New Hematologic Biomarker Test Provides New Approach to Sepsis Triage and Diagnosis
Antibiotics, Statins, and Glucocorticoids All Show Promise
Current, Sole Therapy Not Always Successful/Suitable
Over 1.5 Million Americans Likely to have Wet AMD by 2020 
Potential For Use Against E. Coli, TB, Resistant Bacteria
More Than 32% of Patients Responded in Trial